CDC25A inhibition suppresses cell proliferation and induces G<sub>1</sub>/S‑phase cell cycle arrest in nasopharyngeal carcinoma

Wang,Bin; Gong,Qiaohong; Chen,Fuhai

doi:10.3892/mmr.2023.12996

CDC25A inhibition suppresses cell proliferation and induces G₁/S‑phase cell cycle arrest in nasopharyngeal carcinoma

Authors:
- Bin Wang
- Qiaohong Gong
- Fuhai Chen
View Affiliations

Affiliations: Department of Otolaryngology‑Head and Neck Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P.R. China, Department of Preventive Medicine, Hangzhou Obstetrics and Gynecology Hospital, Hangzhou, Zhejiang 310008, P.R. China
Published online on: April 12, 2023 https://doi.org/10.3892/mmr.2023.12996
Article Number: 109
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a primary malignancy that originates from the nasopharyngeal region. It has been demonstrated that a decrease in the expression level of cell division cycle gene 25A (CDC25A) suppresses cell viability and induces apoptosis in a variety of different types of cancer. However, at present, the role of CDC25A in NPC has yet to be fully elucidated. Therefore, the aim of the present study was to investigate the role of CDC25A in NPC progression and to explore the potential underlying mechanism. Reverse transcription‑quantitative PCR was performed to detect the relative mRNA levels of CDC25A and E2F transcription factor 1 (E2F1). Western blot analysis was subsequently used to determine the expression levels of CDC25A, Ki67, proliferating cell nuclear antigen (PCNA) and E2F1. CCK8 assay was employed to measure cell viability and flow cytometric analysis was employed to analyze the cell cycle. The binding sites between the CDC25A promoter and E2F1 were predicted using bioinformatics tools. Finally, luciferase reporter gene and chromatin immunoprecipitation assays were performed to verify the interaction between CDC25A and E2F1. The results obtained suggested that CDC25A is highly expressed in NPC cell lines and CDC25A silencing was found to inhibit cell proliferation, reduce the protein expression levels of Ki67 and PCNA and induce G1 arrest of NPC cells. Furthermore, E2F1 could bind CDC25A and positively regulate its expression at the transcriptional level. In addition, CDC25A silencing abolished the effects of E2F1 overexpression on cell proliferation and the cell cycle in NPC. Taken together, the findings of the present study showed that CDC25A silencing attenuated cell proliferation and induced cell cycle arrest in NPC and CDC25A was regulated by E2F1. Hence, CDC25A may be a promising therapeutic target for treatment of NPC.

View Figures

View References

1	Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M, Zhang J, Ren X, Wang Y, Yang X, et al: m⁶A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 9:11692018. View Article : Google Scholar : PubMed/NCBI
2	Chow JC, Ngan RK, Cheung KM and Cho WC: Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opin Biol Ther. 19:1165–1172. 2019. View Article : Google Scholar : PubMed/NCBI
3	Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL, Lv JW, Huang XD, Liu RQ, Chen F, He XJ, et al: Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. Cancer Res. 79:4612–4626. 2019. View Article : Google Scholar : PubMed/NCBI
4	Lee HM, Okuda KS, González FE and Patel V: Current perspectives on nasopharyngeal carcinoma. Adv Exp Med Biol. 1164:11–34. 2019. View Article : Google Scholar : PubMed/NCBI
5	Guo Y, Zhai J, Zhang J, Ni C and Zhou H: Improved radiotherapy sensitivity of nasopharyngeal carcinoma cells by miR-29-3p targeting COL1A1 3′-UTR. Med Sci Monit. 25:3161–3169. 2019. View Article : Google Scholar : PubMed/NCBI
6	Brenner AK, Reikvam H, Lavecchia A and Bruserud Ø: Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia-the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 19:18414–18447. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lin TC, Lin PL, Cheng YW, Wu TC, Chou MC, Chen CY and Lee H: MicroRNA-184 deregulated by the MicroRNA-21 promotes tumor malignancy and poor outcomes in non-small cell lung cancer via targeting CDC25A and c-Myc. Ann Surg Oncol. 22 (Suppl 3):S1532–S1539. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ding FN, Gao BH, Wu X, Gong CW, Wang WQ and Zhang SM: miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25A (CDC25A). FEBS Open Bio. 9:1869–1879. 2019. View Article : Google Scholar : PubMed/NCBI
9	Pu L, Su L and Kang X: The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2. Int J Mol Med. 44:57–66. 2019.PubMed/NCBI
10	Li MY, Liu JQ, Chen DP, Li ZY, Qi B, He L, Yu Y, Yin WJ, Wang MY and Lin L: Radiotherapy induces cell cycle arrest and cell apoptosis in nasopharyngeal carcinoma via the ATM and Smad pathways. Cancer Biol Ther. 18:681–693. 2017. View Article : Google Scholar : PubMed/NCBI
11	Denechaud PD, Fajas L and Giralt A: E2F1, a novel regulator of metabolism. Front Endocrinol (Lausanne). 8:3112017. View Article : Google Scholar : PubMed/NCBI
12	Shen C, Li J, Chang S and Che G: Advancement of E2F1 in common tumors. Zhongguo Fei Ai Za Zhi. 23:921–926. 2020.(In Chinese). PubMed/NCBI
13	Farra R, Dapas B, Grassi M, Benedetti F and Grassi G: E2F1 as a molecular drug target in ovarian cancer. Expert Opin Ther Targets. 23:161–164. 2019. View Article : Google Scholar : PubMed/NCBI
14	Bi XC, Pu XY, Liu JM and Huang S: Effect of transcription factor E2F1 expression on the invasion of prostate cancer. Zhonghua Yi Xue Za Zhi. 97:2856–2859. 2017.(In Chinese). PubMed/NCBI
15	Godoy PRDV, Donaires FS, Montaldi APL and Sakamoto-Hojo ET: Anti-proliferative effects of E2F1 suppression in glioblastoma cells. Cytogenet Genome Res. 161:372–381. 2021. View Article : Google Scholar : PubMed/NCBI
16	Liu P, Zhang X, Li Z, Wei L, Peng Q, Liu C, Wu Y, Yan Q and Ma J: A significant role of transcription factors E2F in inflammation and tumorigenesis of nasopharyngeal carcinoma. Biochem Biophys Res Commun. 524:816–824. 2020. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Nie P and Zhu D: LncRNA HOXA10-AS activated by E2F1 facilitates proliferation and migration of nasopharyngeal carcinoma cells through sponging miR-582-3p to upregulate RAB31. Am J Rhinol Allergy. 36:348–359. 2022. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ru Lee W, Chen CC, Liu S and Safe S: 17beta-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways. J Cell Biochem. 99:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
20	Xiao Z and Chen Z: Deciphering nasopharyngeal carcinoma pathogenesis via proteomics. Expert Rev Proteomics. 16:475–485. 2019. View Article : Google Scholar : PubMed/NCBI
21	Qin H and Liu W: MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A. J Cell Physiol. 234:3526–3537. 2019. View Article : Google Scholar : PubMed/NCBI
22	Sun Y, Li S, Yang L, Zhang D, Zhao Z, Gao J and Liu L: CDC25A facilitates chemo-resistance in ovarian cancer multicellular spheroids by promoting E-cadherin expression and arresting cell cycles. J Cancer. 10:2874–2884. 2019. View Article : Google Scholar : PubMed/NCBI
23	Yin W, Xu J, Li C, Dai X, Wu T and Wen J: Circular RNA circ_0007142 facilitates colorectal cancer progression by modulating CDC25A expression via miR-122-5p. Onco Targets Ther. 13:3689–3701. 2020. View Article : Google Scholar : PubMed/NCBI
24	Jiang T and Cheng H: miR-34a-5p blocks cervical cancer growth and migration by downregulating CDC25A. J BUON. 26:1768–1774. 2021.PubMed/NCBI
25	Liu P, Xia P, Fu Q, Liu C, Luo Q, Cheng L, Yu P, Qin T and Zhang H: miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest. Biochem Biophys Res Commun. 571:96–103. 2021. View Article : Google Scholar : PubMed/NCBI
26	Sadeghi H, Golalipour M, Yamchi A, Farazmandfar T and Shahbazi M: CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation. J Cell Biochem. 120:2919–2928. 2019. View Article : Google Scholar : PubMed/NCBI
27	Shen T and Huang S: The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
28	Sun X and Kaufman PD: Ki-67: More than a proliferation marker. Chromosoma. 127:175–186. 2018. View Article : Google Scholar : PubMed/NCBI
29	Worby CA and Dixon JE: PTEN. Annu Rev Biochem. 83:641–669. 2014. View Article : Google Scholar : PubMed/NCBI
30	Wang Z, Wang Y, Wang S, Meng X, Song F, Huo W, Zhang S, Chang J, Li J, Zheng B, et al: Coxsackievirus A6 induces cell cycle arrest in G0/G1 phase for viral production. Front Cell Infect Microbiol. 8:2792018. View Article : Google Scholar : PubMed/NCBI
31	Ditano JP, Sakurikar N and Eastman A: Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition. Cell Cycle. 20:1308–1319. 2021. View Article : Google Scholar : PubMed/NCBI
32	Ma Y, Wang R, Lu H, Li X, Zhang G, Fu F, Cao L, Zhan S, Wang Z, Deng Z, et al: B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A. J Cancer. 11:2158–2170. 2020. View Article : Google Scholar : PubMed/NCBI
33	Tang Y, Jiang L, Zhao X, Hu D, Zhao G, Luo S, Du X and Tang W: FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression. Cell Biol Int. 45:2510–2520. 2021. View Article : Google Scholar : PubMed/NCBI
34	Ma J, He Z, Zhang H, Zhang W, Gao S and Ni X: SEC61G promotes breast cancer development and metastasis via modulating glycolysis and is transcriptionally regulated by E2F1. Cell Death Dis. 12:5502021. View Article : Google Scholar : PubMed/NCBI
35	Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, Nikiteas N, Pazaiti A, Kittas C, Bastounis E and Gorgoulis VG: E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res. 24:3041–3047. 2004.PubMed/NCBI
36	Chan AB, Huber AL and Lamia KA: Cryptochromes modulate E2F family transcription factors. Sci Rep. 10:40772020. View Article : Google Scholar : PubMed/NCBI
37	Tan Y, Wei X, Zhang W, Wang X, Wang K, Du B and Xiao J: Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. Oncol Rep. 37:1833–1841. 2017. View Article : Google Scholar : PubMed/NCBI